



Pressrelease  
Lund, Sweden 2019-06-04

## **CLS' products and method are planned to be used in a clinical trial, carried out by Immunophotonics, regarding evaluation of new drug**

[Clinical Laserthermia Systems AB](#) (publ) (CLS) is preparing to enter into an agreement under which the company's technology and products will be used in a clinical trial, carried out by the American biotech company Immunophotonics Inc. The purpose of the trial is to evaluate the efficacy of a new IP-001-drug from Immunophotonics, developed to create, or enhance, an immune response in connection with ablation treatment. The trial, planned to be carried out at a number of hospitals in Switzerland, will be financed by Immunophotonics. More information about the collaboration will be announced when the parties have signed the agreement.

### [About Immunophotonics](#)

*This press release has been translated from Swedish. The Swedish text shall govern for all purposes and prevail in case of any discrepancy with the English version.*

#### **Company Contact:**

Lars-Erik Eriksson, CEO Clinical Laserthermia Systems AB (publ)  
Tel: +46 – (0)702 – 90 33 00 E-mail: [lee@clinicallaser.se](mailto:lee@clinicallaser.se)

***Clinical Laserthermia Systems AB (publ)**, develops and sells the TRANBERG®|Thermal Therapy System and specially designed sterile disposable products for safe, gentle and effective treatment of cancerous tumors. The products are marketed for image-guided laser ablation and for treatment with immuno-stimulating interstitial laser thermotherapy, imILT®. The company, which is headquartered in Lund Sweden and has a subsidiary in Berlin, Germany and Irvine, CA, USA, is listed Nasdaq First North under the ticker CLS B. Certified Adviser: Västra Hamnen Corporate Finance AB, Tel: +46 40 200 250E-mail: [ca@vhcorp.se](mailto:ca@vhcorp.se). Further information is available on [www.clinicallaser.se](http://www.clinicallaser.se)*